The Global Health Body Raises Concern Over Acute Lack of Obesity Medications
Fewer than one in 10 patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it publishes its initial recommendations on the drugs.
Given more than one billion individuals worldwide currently living with obesity, it is urging broader and more equitable availability to this class of drugs.
According to projections, more than two billion are projected to be obese by 2030 without intervention.
"Our latest guidance acknowledges that obesity is a long-term condition that can be managed with thorough and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key obstacles to widespread access to the injections that can help people shift substantial weight, says the agency.
Weight-Loss Drug Supply Crisis
Despite the current most optimistic case, the manufacturing of such drugs might only reach about 100 million people – under 10% of the global need, as stated by the WHO.
The recommendation encourages countries and companies to expand access, through measures including patent sharing.
Exclusive production rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is due to expire in multiple nations in 2026.
How Obesity Jabs Operate
The injections mimick a biological compound to delay gastric emptying, curb appetite and increase feelings of fullness so individuals eat less.
Patients commonly begin shedding pounds in the initial weeks of beginning the weekly injections.
Evidence indicates patients may see weight return after a year of discontinuing the drug, because their usual hunger resume.
To be above a healthy weight elevates your likelihood for contracting health problems, including type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity affects people in all nations and was associated with over three and a half million deaths worldwide in 2024, per the WHO.
